Marine organisms are an excellent source of structurally diverse molecules which are potentially useful for drug discovery.1) Several marine natural products have been discovered as lead compounds in various therapeutic areas, and some of them are currently in clinical studies.2,3) In our marine natural product research program, we have built a marine fraction library (MFL) for high throughput screening (HTS) for a variety of biological targets.4) The active fractions are followed up using bioassay-guided fractionation to identify the active compounds. Isolation and identification of CCR7 receptor binding inhibitors from the marine sponge Ircinia sp. are described in this paper.
Chemokines and their receptors play important roles in many biological cascades, including allergic, inflammatory and metastatic processes. As such, small molecule agonists and antagonists of chemokine receptors have many potential therapeutic applications. The chemokine receptor, CCR7, is activated by CCL19 and CCL29 and regulates the mobilization of T cells and dentritic cells into the T cell areas of secondary lymphoid organs.5) Therefore, CCR7
mediates an essential event for antigen-specific T cell activation and an important mechanism for mounting an immune response.6) Thus, CCR7 could be a potential target for treatment of various metastases and/or inflammatory conditions.
In this study, a fraction from a sponge was identified which showed inhibitory activity in the CCR7 receptor In the primary HTS assay, a sample in the MFL from a active fraction was subjected to further purification. The preliminary CG161 fractions were prepared as previously described.4,8) In this study, fraction 3 (50% acetonitrile (ACN) elution) was active in the CCR7 binding assay. Fraction 3 (35mg) was further purified on an HPLC ACN gradient system (15ml/minute, 2% to 30% ACN over 40 minutes, and 30% to 70% ACN over next 40 minutes), to yield -100 fractions (13ml/fraction). Two pure compounds 2 (1.8mg) and 1 (0.9mg) were obtained with retention time -54 minutes and -57 minutes, respectively. Detailed NMR analysis9) idetified 2 as sulfircin, a compound whose structure had been determined previously by X-ray crystallography.10)
The structure of 1 was determined based on extensive NMR and HRMS analyses and by comparison to 2.11) From interpretation of the HSQC-TOCSY spectrum as shown in Figure 1 . Therefore the sulfate group could only be located at the C-12 position and the planar structure of Sch 599473
(1) was unambiguously determined. Trans configuration of the bicyclic structure in 1 was identified by its NMR data as well as in comparison with the NMR data to those of the model compounds, luffarins,12) which have the identical bicyclic skeleton as 1 and their stereochemistry on the bicyclic ring have been established.12-14) The coupling pattern of H-5 (dd, J=12.5, 2.0Hz) in 1 indicated that H-5 was in the axial position. The same coupling pattern (H-5, dd, J=12.7, 2.0Hz) was observed in the 1H NMR of luffarin E (3). This type of coupling pattern would not be observed when the bicyclic Figure 2 .
Therefore, the relative stereochemistry of the bicyclic ring was assigned to trans configuration.
The stereochemistry at C-12 and C-13 positions could not be defined by NMR methods. However, based upon the similarity of the NMR spectra of 1 and 2, it is highly likely that they share the same stereochemistry.
Compound 2 exhibited fairly potent inhibitory activity in the CCR7 receptor binding assay. The IC50 values of 1 and respectively. The significant decrease of the activity of 1 in comparison to 2 indicated that the double bond shift from
